{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:14:05Z","timestamp":1788902045999,"version":"build-2803163510"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>F-18 DOPA PET\/CT is well established in the evaluation of neuroendocrine tumors and pheochromocytoma\/paraganglioma. Prostatic uptake is not part of its usual physiological biodistribution, and its significance in conventional prostate adenocarcinoma remains unclear. We report intense incidental prostatic F-18 DOPA uptake in a 60-year-old man undergoing evaluation for persistently elevated normetanephrines. PET\/CT showed 2 highly avid foci in the posterior-inferior prostate. Multiparametric MRI was not suspicious, but biopsy revealed acinar adenocarcinoma, Gleason score 3+3, ISUP grade 1, without neuroendocrine marker expression. This finding represents a potential diagnostic pitfall and supports cautious interpretation of focal pelvic F-18 DOPA uptake.<\/jats:p>","DOI":"10.1097\/rlu.0000000000006596","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:13:46Z","timestamp":1782850426000},"page":"e953-e954","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6187-7696","authenticated-orcid":false,"given":"Carlos","family":"Mas Pascasio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Ru\u00edz de Almir\u00f3n de Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"L\u00f3pez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Sanz Viedma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 guidelines for radionuclide imaging of pheochromocytoma and paraganglioma","volume":"39","author":"Ta\u00efeb","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","article-title":"Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cen.12566","article-title":"Role of 18F-FDOPA PET\/CT imaging in endocrinology","volume":"81","author":"Santhanam","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R4-20260908","first-page":"35","article-title":"The current role of 18F-FDOPA PET for neuroendocrine tumor imaging","volume":"40","author":"Lussey-Lepoutre","year":"2016","journal-title":"Med Nucl"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J Nucl Med"},{"issue":"suppl 1","key":"R6-20260908","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00259-013-2361-7","article-title":"Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET\/CT: utility and limitations","volume":"40","author":"Jadvar","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260908","first-page":"367","article-title":"PET\/CT in prostate cancer: non-choline radiopharmaceuticals","volume":"56","author":"Castellucci","year":"2012","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging","volume":"44","author":"Sheikhbahaei","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:00:48Z","timestamp":1788901248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006596"}},"subtitle":["A Potential Diagnostic Pitfall"],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006596","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"2026-04-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}